[REVISION HISTORY]

Advancements in Alzheimer's blood test detection

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-28 09:28 UTC → 2026-08-29 12:07 UTC · added ~~removed~~

Research led by neurologist Allal Boutjankout and NYU professor Thomas Wisniewski demonstrated that blood tests measuring plasma levels of beta-amyloid, tau, and inflammation-related proteins can identify Alzheimer’s disease biomarkers. The study indicated these markers could signal disease onset eight to ten years before clinical symptoms appear, potentially offering a lower-cost alternative to PET scans. Following these developments, the U.S. Food and Drug Administration (FDA) ~~approved two new~~ cleared several blood tests for Alzheimer’s detection. C2N Diagnostics received approval for the PrecivityAD2 test, which uses mass spectrometry to measure ~~protein levels~~ amyloid and ~~showed~~ tau proteins. Clinical studies reported a 97.6% accuracy ~~rate in clinical studies.~~ rate, and the test is available for individuals aged 40 and older experiencing cognitive complaints. Additionally, the FDA ~~approved~~ cleared the Elecsys ~~pTau217~~ pTau-217 test, a collaboration between Roche and Eli ~~Lilly, designed to identify the likelihood of Alzheimer’s-related brain changes in~~ Lilly. Designed for individuals aged 55 and ~~older.~~ older showing signs of cognitive decline, it is the first test to measure a single biomarker, plasma phosphorylated tau 217, and is compatible with over 4,500 analyzers across the United States. These advancements follow a previous 2025 clearance of a Fujirebio Diagnostics test. While these tests offer a less invasive alternative to spinal fluid exams and PET scans, medical experts note they should not be used as a “sole definitive diagnosis without clinical context.”

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.